Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes

Movement Disorders

Volumn 25, Issue 9, 2010, Pages 1284-1288

  Süssmuth, Sigurd D ^a   Uttner, Ingo ^a   Landwehrmeyer, Bernhard ^a   Pinkhardt, Elmar H ^a   Brettschneider, Johannes ^a   Petzold, Axel ^b   Kramer, Bernd ^a   Schulz, Jörg B ^c   Palm, Christian ^a   Otto, Markus ^a   Ludolph, Albert C ^a   Kassubek, Jan ^a   Tumani, Hayrettin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Biomarker; Cerebrospinal fluid; Multiple system atrophy; Progressive supranuclear palsy; PSP P; Richardson's syndrome

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; SERUM ALBUMIN; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GLIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RICHARDSON SYNDROME; SHY DRAGER SYNDROME; SYNDROME; CEREBROSPINAL FLUID; MIDDLE AGED; NONPARAMETRIC TEST; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 77955073900     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22895     Document Type: Article

References (33)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
2. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(Pt 4):861-870. (Pubitemid 34279780)
3. Litvan I. Recent advances in atypical parkinsonian disorders. Curr Opin Neurol 1999;12:441-446. (Pubitemid 30028742)
4. Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004;19:181-189.
5. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991; 18:275-278.
6. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989;Suppl:78-89. (Pubitemid 19167883)
7. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
8. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
9. Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997;236:262-264.
10. Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-98.
11. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005;237(1-2):61-65. (Pubitemid 41384015)
12. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186-190. (Pubitemid 36305463)
13. Abdo WF, De Jong D, Hendriks JC, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 2004;19:571-579.
14. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-77. (Pubitemid 28029855)
15. Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006; 21:2224-2227.
16. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128(Pt 6):1247-1258.
17. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98. (Pubitemid 29155424)
18. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287(1-2):169-177. (Pubitemid 38510218)
19. Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997;120(Pt 1):65-74.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
21. Fahn S, Elton RL, Committee UD. Unified Parkinson's Disease Rating Scale: Florham Park, NJ: Macmillan Healthcare Information; 1987.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
23. Mattis S. Dementia Rating Scale: Professional manual: Odessa, FL: Psychological Assessment Resources Inc.; 1988.
24. Süssmuth SD, Brettschneider J, Ludolph AC, Tumani H. Biochemical markers in CSF of ALS patients. Curr Med Chem 2008;15:1788-1801.
25. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol 2005;252:1067-1073. (Pubitemid 41355837)
26. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
27. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord 2007;13:480-482.
28. Sobue G, Hashizume Y, Mitsuma T, Takahashi A. Size-dependent myelinated fiber loss in the corticospinal tract in Shy-Drager syndrome and amyotrophic lateral sclerosis. Neurology 1987;37: 529-532. (Pubitemid 17031764)
29. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130(Pt 6):1566-1576. (Pubitemid 47355935)
30. Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 1990;119:182-186.
31. Primavera J, Lu BX, Riskind PJ, Iulian M, De La Monte SM. Brain Accumulation of Amyloid-beta in Non-Alzheimer Neurodegeneration. J Alzheimers Dis 1999;1:183-193.
32. Verbeek MM, Abdo WF, De Jong D, Horstink MW, Kremer BP, Bloem BR. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Mov Disord 2004;19:238-240; author reply 240-231.
33. Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389-1392.